AGEN Quote, Financials, Valuation and Earnings

Bionano Genomics, Inc. has a net margin of -116.82% compared to Agenus, Inc.'s net margin of -115.42%. Agenus, Inc.'s return on equity of -- beat Bionano Genomics, Inc.'s return on equity of -84.77%.

Agenus, Inc. has a consensus price target of $12.33, signalling upside risk potential of 264.89%. On the other hand Bionano Genomics, Inc. has an analysts' consensus of $7.50 which suggests that it could grow by 349.1%. Given that Bionano Genomics, Inc. has higher upside potential than Agenus, Inc., analysts believe Bionano Genomics, Inc. is more attractive than Agenus, Inc..

Agenus, Inc. has a beta of 1.577, which suggesting that the stock is 57.698% more volatile than S&P 500. In comparison Bionano Genomics, Inc. has a beta of 1.141, suggesting its more volatile than the S&P 500 by 14.145%.

Agenus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus, Inc. pays -- of its earnings as a dividend. Bionano Genomics, Inc. pays out -- of its earnings as a dividend.

Agenus, Inc. quarterly revenues are $30.2M, which are larger than Bionano Genomics, Inc. quarterly revenues of $7.4M. Agenus, Inc.'s net income of $63.9M is higher than Bionano Genomics, Inc.'s net income of -$8.5M. Notably, Agenus, Inc.'s price-to-earnings ratio is -- while Bionano Genomics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus, Inc. is 0.85x versus 0.19x for Bionano Genomics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cardiff Oncology, Inc. has a net margin of -116.82% compared to Agenus, Inc.'s net margin of -9381.67%. Agenus, Inc.'s return on equity of -- beat Cardiff Oncology, Inc.'s return on equity of -81.17%.

Agenus, Inc. has a consensus price target of $12.33, signalling upside risk potential of 264.89%. On the other hand Cardiff Oncology, Inc. has an analysts' consensus of $9.75 which suggests that it could grow by 236.7%. Given that Agenus, Inc. has higher upside potential than Cardiff Oncology, Inc., analysts believe Agenus, Inc. is more attractive than Cardiff Oncology, Inc..

Agenus, Inc. has a beta of 1.577, which suggesting that the stock is 57.698% more volatile than S&P 500. In comparison Cardiff Oncology, Inc. has a beta of 1.397, suggesting its more volatile than the S&P 500 by 39.746%.

Agenus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cardiff Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus, Inc. pays -- of its earnings as a dividend. Cardiff Oncology, Inc. pays out -- of its earnings as a dividend.

Agenus, Inc. quarterly revenues are $30.2M, which are larger than Cardiff Oncology, Inc. quarterly revenues of $120K. Agenus, Inc.'s net income of $63.9M is higher than Cardiff Oncology, Inc.'s net income of -$11.3M. Notably, Agenus, Inc.'s price-to-earnings ratio is -- while Cardiff Oncology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus, Inc. is 0.85x versus 378.17x for Cardiff Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Inovio Pharmaceuticals, Inc. has a net margin of -116.82% compared to Agenus, Inc.'s net margin of -30140.49%. Agenus, Inc.'s return on equity of -- beat Inovio Pharmaceuticals, Inc.'s return on equity of -252.43%.

Agenus, Inc. has a consensus price target of $12.33, signalling upside risk potential of 264.89%. On the other hand Inovio Pharmaceuticals, Inc. has an analysts' consensus of $7.63 which suggests that it could grow by 389.32%. Given that Inovio Pharmaceuticals, Inc. has higher upside potential than Agenus, Inc., analysts believe Inovio Pharmaceuticals, Inc. is more attractive than Agenus, Inc..

Agenus, Inc. has a beta of 1.577, which suggesting that the stock is 57.698% more volatile than S&P 500. In comparison Inovio Pharmaceuticals, Inc. has a beta of 1.618, suggesting its more volatile than the S&P 500 by 61.808%.

Agenus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus, Inc. pays -- of its earnings as a dividend. Inovio Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Agenus, Inc. quarterly revenues are $30.2M, which are larger than Inovio Pharmaceuticals, Inc. quarterly revenues of --. Agenus, Inc.'s net income of $63.9M is higher than Inovio Pharmaceuticals, Inc.'s net income of -$45.5M. Notably, Agenus, Inc.'s price-to-earnings ratio is -- while Inovio Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus, Inc. is 0.85x versus 346.72x for Inovio Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Twist Bioscience Corp. has a net margin of -116.82% compared to Agenus, Inc.'s net margin of -27.41%. Agenus, Inc.'s return on equity of -- beat Twist Bioscience Corp.'s return on equity of -16.74%.

Agenus, Inc. has a consensus price target of $12.33, signalling upside risk potential of 264.89%. On the other hand Twist Bioscience Corp. has an analysts' consensus of $40.50 which suggests that it could fall by -10.3%. Given that Agenus, Inc. has higher upside potential than Twist Bioscience Corp., analysts believe Agenus, Inc. is more attractive than Twist Bioscience Corp..

Agenus, Inc. has a beta of 1.577, which suggesting that the stock is 57.698% more volatile than S&P 500. In comparison Twist Bioscience Corp. has a beta of 2.191, suggesting its more volatile than the S&P 500 by 119.099%.

Agenus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Twist Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agenus, Inc. pays -- of its earnings as a dividend. Twist Bioscience Corp. pays out -- of its earnings as a dividend.

Agenus, Inc. quarterly revenues are $30.2M, which are smaller than Twist Bioscience Corp. quarterly revenues of $99M. Agenus, Inc.'s net income of $63.9M is higher than Twist Bioscience Corp.'s net income of -$27.1M. Notably, Agenus, Inc.'s price-to-earnings ratio is -- while Twist Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agenus, Inc. is 0.85x versus 7.21x for Twist Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.